Related references
Note: Only part of the references are listed.Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond
Caterina Marchio et al.
SEMINARS IN CANCER BIOLOGY (2021)
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
Aleix Prat et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Results of a Randomized Phase IIb Trial of Nelipepimut-S thorn Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer
G. Travis Clifton et al.
CLINICAL CANCER RESEARCH (2020)
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
Ana Lluch et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+or 2+
Louis Fehrenbacher et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study
Shanu Modi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial
Aleix Prat et al.
LANCET ONCOLOGY (2020)
ERBB2mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
Gaia Griguolo et al.
CANCERS (2020)
PF-06804103, A Site-specific Anti-HER2 Antibody-Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
Edmund Graziani et al.
MOLECULAR CANCER THERAPEUTICS (2020)
HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
Gabriel Rinnerthaler et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
Udai Banerji et al.
LANCET ONCOLOGY (2019)
Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial
Barbara Adamo et al.
BREAST CANCER RESEARCH (2019)
Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancer
Swati Gupta et al.
NPJ BREAST CANCER (2019)
The Dilemma of HER2 Double-equivocal Breast Carcinomas Genomic Profiling and Implications for Treatment
Caterina Marchio et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Pedram Razavi et al.
CANCER CELL (2018)
Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.
Hiroji Iwata et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer
Aranzazu Fernandez-Martinez et al.
ONCOTARGET (2017)
Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib
Aleix Prat et al.
JAMA ONCOLOGY (2016)
Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer
Giovanni Ciriello et al.
CELL (2015)
A Retrospective Population-Based Comparison of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization in Breast Carcinomas Impact of 2007 American Society of Clinical Oncology/College of American Pathologists Criteria
Kurt A. Schalper et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2014)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Practical implications of gene-expression-based assays for breast oncologists
Aleix Prat et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Population-based Estimate of the Prevalence of HER-2 Positive Breast Cancer Tumors for Early Stage Patients in the US
Kathleen A. Cronin et al.
CANCER INVESTIGATION (2010)
Direct multiplexed measurement of gene expression with color-coded probe pairs
Gary K. Geiss et al.
NATURE BIOTECHNOLOGY (2008)
Share Paper
